



SIGA Announces Canadian Department of National Defence Intent to Purchase Up To 15,325 Courses of Oral TPOXX®

December 5, 2019

- **Contract Would Represent First International Order of TPOXX**
- **Canadian Military Intends Firm Delivery of 2,500 Courses, with Additional Option Quantities of 12,825 Courses**

NEW YORK, Dec. 05, 2019 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the Canadian Department of National Defence (CDND) has issued an advanced contract award notice (ACAN), indicating that the CDND intends to purchase up to 15,325 courses of oral TPOXX (tecovirimat) over four years as specified in the ACAN, with an initial purchase of 2,500 courses. The ACAN is required to remain open for at least 15 days, during which time a potential alternative supplier may submit a competing Statement of Capabilities. The contract would represent the first international order for TPOXX. As SIGA previously announced, the CDND intends to award a contract to support regulatory approval for TPOXX by Health Canada. The Company is currently targeting a Canadian regulatory filing in the second half of 2020, with regulatory approval anticipated in 2021.

"This type of initial procurement by the Canadian military, in advance of Canadian regulatory approval, would be a natural first step in our efforts to build an international business for oral TPOXX. We are pleased that the value of TPOXX as an important component of smallpox preparedness is being recognized outside the United States," said Dr. Phil Gomez, CEO of SIGA Technologies. "Historically, the military is often the first governmental department to acquire a medical countermeasure for national preparedness, with health departments often following at a later date with significantly larger contract awards. Specifically with respect to Canada, we are working collaboratively with our partner, Meridian Medical Technologies, Inc., and both the Department of Defence and Health Ministries to support procurement needs for TPOXX to protect Canada's military and civilian population."

The value of courses to be sold to Canada will be disclosed upon any final award by the Canadian government. In any contract issued by Canada, Meridian will be the counterparty to the contract and SIGA will be responsible for the manufacture and delivery of product.

The ACAN notice can be found at: <https://buyandsell.gc.ca/procurement-data/tender-notice/PW-PH-893-78161>

On July 13, 2018, the FDA approved oral TPOXX for the treatment of smallpox to mitigate the impact of a potential outbreak or bioterror attack. TPOXX, a small-molecule antiviral treatment for smallpox, is the first therapy specifically approved for this indication, and was developed through funding and collaboration with the Biomedical Advanced Research and Development Authority at the U.S. Department of Health and Human Services, as well as early stage development supported by the National Institutes of Health, U.S. Centers for Disease Control and Prevention, and Department of Defense. The US currently maintains a stockpile of 1.7 million courses of TPOXX.

In June 2019, SIGA entered into an international promotion agreement with Meridian Medical Technologies, Inc. ("Meridian", a Pfizer Company). Under the agreement, Meridian will promote the sale of oral TPOXX for the treatment of smallpox in all international markets, except the United States and South Korea. SIGA will continue to own all rights to the product and its related intellectual property.

ABOUT SIGA TECHNOLOGIES, INC. and TPOXX®

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness. Our lead product is TPOXX®, also known as tecovirimat and ST-246®, an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the US maintains a stockpile of 1.7 million oral courses in the Strategic National Stockpile under Project BioShield. The oral formulation of TPOXX was approved by the FDA for the treatment of smallpox on July 13, 2018. In September 2018, SIGA signed a contract with Biomedical Advanced Research and Development Authority (BARDA) for additional procurement and development related to both oral and intravenous formulations of TPOXX. For more information about SIGA, please visit www.siga.com.

ABOUT MERIDIAN MEDICAL TECHNOLOGIES, INC.

Meridian Medical Technologies, Inc., a Pfizer company, has been putting emergency care treatment options into the hands of military and civilian defenders for more than 50 years. Meridian is committed to help defend against critical, time-sensitive, life-or-death situations by providing medical countermeasures to the United States Department of Defense, Emergency Medical Services, Homeland Security, and more than 30 nations around the world.

Meridian holds a federal SAFETY Act designation and certification from the Department of Homeland Security for its portfolio of auto-injectors. The SAFETY Act is intended to provide critical incentives for the development and deployment of anti-terrorism technologies by providing liability protections for sellers of qualified anti-terrorism technologies.

About Smallpox¹

Smallpox is a contagious, disfiguring and often deadly disease that has affected humans for thousands of years. Naturally occurring smallpox was eradicated worldwide by 1980, the result of an unprecedented global immunization campaign. Samples of smallpox virus have been kept for research purposes. This has led to concerns that smallpox could someday be used as a biological warfare agent. A vaccine can prevent smallpox, but the risk of the current vaccine's side effects is too high to justify routine vaccination for people at low risk of exposure to the smallpox virus.

FORWARD-LOOKING STATEMENTS

This press release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are subject to various known and unknown risks and uncertainties, and SIGA cautions you that any forward-looking information provided by or on behalf of SIGA is not a guarantee of future performance. More detailed information about SIGA and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this press release, is set forth in SIGA's filings with the Securities and Exchange Commission, including SIGA's Annual Report on Form 10-K for the fiscal year ended December 31, 2018, and in other documents that SIGA has filed with the SEC. SIGA urges investors and security holders to read those documents free of charge at the SEC's web site at <http://www.sec.gov>. Interested parties may also obtain those documents free of charge from SIGA. Forward-looking statements are current only as of the date on which such statements were made, and except for our ongoing obligations under the United States of America federal securities laws, we undertake no obligation to update publicly any forward-looking statements whether as a result of new information, future events, or otherwise.

The information contained in this press release does not necessarily reflect the position or the policy of the Government and no official endorsement should be inferred.

Contacts:

Investors

David Carey

212-867-1768

david.carey@finnpartners.com

Media

Stephanie Seiler

206-713-0124

stephanie.seiler@finnpartners.com

¹ <http://www.mayoclinic.org/diseases-conditions/smallpox/basics/definition/con-20022769>



Source: SIGA Technologies Inc.